Alimentiv Expands Partnership with Satisfai Health to Enhance IBD Imaging Solutions

• Alimentiv has expanded its partnership with Satisfai Health to include the use of Certai, an AI scoring software designed for ulcerative colitis clinical trials.

• The integration aims to improve the quality and efficiency of trial analyses by leveraging advanced medical imaging solutions.

Alimentiv, a full-service contract research organisation (CRO) focused on gastrointestinal (GI) diseases, has announced the expansion of its collaboration with Satisfai Health. This partnership will enhance the capabilities of Certai, an AI-powered assistive scoring software specifically designed for ulcerative colitis (UC) assessments in clinical trials. The enhanced analysis aims to improve the quality and efficiency of clinical trials by providing precise disease activity assessments.

The Certai software was developed using a diverse and anonymized global dataset of IBD colonoscopy videos. This data was labelled and validated under the clinical oversight of leading international IBD experts, ensuring high-quality results. The technology is integrated into Alimentiv’s multi-modal imaging platform, Notō, which supports various imaging modalities, including endoscopy and histopathology.

“AI-powered standardization of disease scoring provides unprecedented insights, transforming data analysis and ultimately leading to better treatment outcomes for patients in clinical trials,” said Pierre Gaudreault, CEO of Alimentiv. He highlighted the company’s commitment to investing in innovative imaging solutions to provide more accurate analyses and competitive trial costs.

The use of Certai is positioned to enhance the overall effectiveness of IBD research by providing sponsors with improved tools for video analysis. However, it is important to note that Certai is not a medical device and is not intended for clinical decision-making or patient care.